SHARDACROP Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,289 Cr
verified against source
Revenue YoY
39%
reported change
EBITDA
₹245.5 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sharda Cropchem delivered an exceptional Q3 FY26 with revenue of Rs 1,289 crore (+39% YoY), driven by 14% volume growth and favorable product mix. Agrochemical segment surged 48% YoY to Rs 1,141 crore while non-agrochemicals grew 8.1% to Rs 148 crore. Gross margins expanded 220bps to 34.9% on input cost stabilization, with management guiding for similar range in FY26 and potential improvement in FY27. EBITDA grew 59% to Rs 245.5 crore with PAT jumping 366% to Rs 145.1 crore versus a low base. Working capital improved significantly to 70 days from 118 days in March 2025. The company is net debt-free with Rs 826 crore cash. Management expects Q4 growth to match Q3 levels and targets 15% volume growth and 15-20% revenue growth in FY27. Key risks include uncertain registration timelines, pricing still below pre-COVID levels despite gradual recovery, and NAFTA region degrowth attributed to unusual climate conditions.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects revenue growth of 15-20% in FY27, with volume growth of approximately 15% achievable. Growth to be driven by continued demand recovery, pricing improvement, and new registrations.
- Company is on track to maintain healthy EBITDA margins in the range of 18-20% for FY26, with potential for further improvement in FY27 as gross margins may go up still further.
- Gross margins expected to remain in similar range (~35%) for FY26, with management indicating it could potentially improve further in FY27.
- Capital expenditure for FY27 is guided in the range of Rs 450-500 crore, though management noted uncertainty due to registration process variables.
Risks flagged
- Chairman explicitly stated registration process is full of uncertainties with timelines ranging from 1 year to 6-7 years due to changing government requirements. This makes FY27 guidance on revenue from new registrations inherently unpredictable.
- Management acknowledged that price realizations are quite down compared to pre-COVID levels, though sourcing costs have also declined. While prices are moving up gradually, the pace is slow and magnitude of recovery is uncertain.
- Chairman deflected questions on China export rebate policy changes, stating Chinese government information is not transparent to foreigners. Though management claimed no current impact, any tightening of agrochemical exports from China could disrupt supply chain.
- NAFTA region witnessed year-on-year degrowth in Q3, attributed to unusual and unpredictable climate conditions. Management provided no clear recovery timeline for this important market contributing ~23.5% gross margin.
Key quotes
- We are very confident that 15% [volume growth] is achievable [for FY27].
- Registration process is full of uncertainties and nobody can predict how much time will it take. A registration may be obtained in one year or two years and the same registration can take six to seven years.
- Prices are also moving up. The speed is less but it is moving up. We expect the growth in our total revenue to be around 15 to 20% in FY27.
Research modules